Dysregulation of heat shock protein 27 expression in oral tongue squamous cell carcinoma

Anxun Wang1, Xiqiang Liu2,3, Shihu Sheng1, Hui Ye2,4, Tingsheng Peng5, Fei Shi6, David L Crowe2,7 and Xiaofeng Zhou*2,3,7

Abstract

Background: Recent proteomic studies identified Hsp27 as a highly over-expressed protein in oral squamous cell carcinoma (OSCC). Clinical studies that attempted to evaluate the prognostic values of Hsp27 yielded inconsistent results, which may be due to inclusion of OSCC cases from multiple anatomic sites. In this study, to determine the utility of Hsp27 for prognosis, we focused on oral tongue SCC (OTSCC), one of the most aggressive forms of OSCC.

Methods: Archival clinical samples of 15 normal oral tongue mucosa, 31 dysplastic lesions, 80 primary OTSCC, and 32 lymph node metastases were examined for Hsp27 expression by immunohistochemistry (IHC). Statistical analyses were carried out to assess the prognostic value of Hsp27 expression for patients with this disease.

Results: Dysregulation of Hsp27 expression was observed in dysplastic lesions, primary OTSCC, and lymph node metastases, and appears to be associated with disease progression. Statistical analysis revealed that the reduced Hsp27 expression in primary tumor tissue was associated with poor differentiation. Furthermore, the higher expression of Hsp27 was correlated with better overall survival.

Conclusion: Our study confirmed that the dysregulation of Hsp27 expression is a frequent event during the progression of OTSCC. The expression of Hsp27 appears to be an independent prognostic marker for patients with this disease.
with different risk factors [1] and genetic characteristics [2]. In this study, we focused on oral tongue (also known as mobile tongue), one of the most common sites for OSCCs. The oral tongue SCC (OTSCC) is more aggressive than other forms of OSCCs, with a propensity for rapid local invasion and spread [3]. The incidence of OTSCC is actually increasing in young and middle age groups [4-6].

Mammalian Hsp27 belongs to the family of proteins that display an enhanced expression in response to various stresses (e.g., heat shock). Several members of the Hsps family (e.g., Hsp90, Hsp70, Hsp27) have been implicated in tumorigenesis, which may be related to their ability to protect cells against spontaneous or stimulated programmed cell death [7]. The cytoprotective properties of the Hsps are closely linked to their primary functions as molecular chaperones. A critical function of Hsp27 is the ability to increase the resistance of cells to oxidative injuries. Hsp27 expression correlates with decreased levels of reactive oxygen species (ROS) and nitric oxide (NO) [8-11].

The enhanced expression of Hsp27 has been associated with poor prognosis in several tumor types (e.g., gastric [12,13], liver [14] and prostate carcinoma [15]), but good prognosis in others (endometrial adenocarcinomas [16,17] and oesophageal cancer [18,19]). Several proteomic studies identified Hsp27 as a highly overexpressed protein in OSCC [20,21]. Our recent proteomic study also demonstrated that higher Hsp27 expression is associated with tongue SCC invasion and metastasis [22]. Several clinical studies have attempted to evaluate the prognostic value of Hsp27 for OSCC, yet yielded inconsistent results [23-28]. This apparent contradiction may partly be due to the inclusion of OSCC cases from multiple anatomic sites. In this study, we evaluate the prognostic significance of Hsp27 focusing on OTSCC, one of the most aggressive forms of OSCC.

Methods

Patients and tissues

The archived tissue samples from 80 cases of OTSCC, 31 cases of dysplastic lesions of the oral tongue and 15 normal tongue biopsies were utilized in this study. Clinical characterization of the OTSCC patients is summarized in Table 1. All OTSCC patients had received curative surgery (resection of the primary tumor and radical neck dissection). None of the patients had received any form of adjuvant therapy prior to their surgery. The tumor extent was classified according to the TMN system by UICC, and the tumor grade was classified according to the WHO classification of histological differentiation. Survival was calcu-

| Table 1: Clinical Characterization of the oral tongue squamous cell carcinoma (OTSCC) Patients* |
|-----------------------------------------------|
| Age | Median (Range) | All OTSCCs (n = 80) | OTSCCs with follow-up data (n = 42) | Dysplastic lesions (n = 31) | Normal (n = 15) |
|-----------------------------------------------|
| Gender | Male: n (%) | 43 (53.75) | 20 (47.62) | 17 (54.84) | 6 (40.00) |
| | Female: n (%) | 37 (46.25) | 22 (52.38) | 14 (45.16) | 9 (60.00) |
| Anatomic Site | Tongue: n (%) | 80 (100) | 42 (100) | 31 (100) | 15 (100) |
| Pathological T Stage | Stage 4: n (%) | 5 (6.25) | 4 (9.52) | 15 (81.25) | 10 (66.67) |
| | Stage 3: n (%) | 14 (17.50) | 8 (19.05) | 16 (84.62) | 16 (106.67) |
| | Stage 2: n (%) | 38 (47.50) | 21 (50.00) | 7 (35.71) | 7 (46.67) |
| | Stage 1: n (%) | 23 (28.75) | 9 (21.43) | 4 (20.83) | 4 (26.67) |
| Pathological N Stage | Stage 2: n (%) | 13 (16.25) | 8 (19.05) | 8 (40.00) | 8 (53.33) |
| | Stage 1: n (%) | 19 (23.75) | 12 (28.57) | 12 (60.00) | 12 (80.00) |
| | Stage 0: n (%) | 48 (60.00) | 22 (52.38) | 11 (55.00) | 11 (73.33) |
| Clinical Stage | Stage 4: n (%) | 15 (18.75) | 10 (23.81) | 10 (52.63) | 6 (40.00) |
| | Stage 3: n (%) | 25 (31.25) | 16 (38.09) | 16 (84.62) | 16 (106.67) |
| | Stage 2: n (%) | 18 (22.50) | 7 (16.67) | 7 (35.71) | 7 (46.67) |
| | Stage 1: n (%) | 22 (27.50) | 9 (21.43) | 4 (20.83) | 4 (26.67) |
| Grade (Differentiation) | Well: n (%) | 46 (57.50) | 25 (59.52) | 25 (129.03) | 16 (106.67) |
| | Mod: n (%) | 20 (25.00) | 7 (16.67) | 7 (35.71) | 7 (46.67) |
| | Poor: n (%) | 14 (17.50) | 10 (23.81) | 4 (20.83) | 4 (26.67) |

* The M stage data is not available.
Kaplan-Meier plots were constructed to present the survival outcomes of high Hsp27 cases (moderate to high staining) and low Hsp27 cases (no or low staining). Cox regression was used for both univariate and multivariate analysis. For multivariate analysis, age, gender, pathological T-stage (pT), pathological N-stage (pN), and clinical stages, grade, Ki67 index, and Hsp27 expression were considered as co-variates. For all statistical analyses, p < 0.05 was considered statistically significant.

**Results**

As illustrated in Figure 1, predominantly cytoplasmic staining for Hsp27 was observed in suprabasal keratinocytes in normal mucosa (Figure 1A). In general, the basal keratinocytes were not immunolabelled by anti-Hsp27 antibody. Among 15 normal mucosa that we examined, 4 cases (26.67%) showed no Hsp27 staining, 8 cases (53.33%) showed low staining, 2 cases (13.33%) showed moderate staining, and 1 case (6.67%) showed high staining. In dysplastic lesions (Figure 1B), the Hsp27 staining was observed in both suprabasal and basal keratinocytes. Of the 31 dysplastic lesions, 1 case (3.23%) showed no Hsp27 staining, 5 cases (16.13%) showed low staining, 11 cases (35.48%) showed moderate staining, and 14 cases (45.16%) showed high staining. In SCC (Figure 1C, D, E), diffuse Hsp27 staining was observed, where the high Hsp27 expression appears to be associated with differentiated areas. Of the 80 cases of primary OTSCC cases, 1 case (1.25%) showed no Hsp27 staining, 20 cases (25%) showed low staining, 42 cases (52.5%) showed moderate staining, and 17 cases (21.25%) showed high staining. For the 32 cases of lymph node metastatic disease (Figure 1F), low staining was observed in 8 cases (25%), moderate staining was observed in 12 cases (37.5%), and high staining was observed in 12 cases (37.5%). Thus, the dysregulation of Hsp27 consists of both the changes in cell population expressing this gene and the alterations in expression level. This change in Hsp27 expression pattern is consistent with our previous observations [22].

Correlations were tested among gene expression (e.g., Hsp27 and Ki67), clinical and Hsp27 expression (Table 2). As expected, strong correlations were observed among pT, pN, and Clinical stage. While correlation between Ki67 index and grading was observed (p < 0.05), a significant inverse correlation was observed between Hsp27 expression and grading (p < 0.01). Interestingly, correlation between Hsp27 expression and age was also observed (p < 0.05).

As illustrated in Figure 1C, D, and 1E, the higher expression of Hsp27 was observed in well and moderately differentiated OTSCC, and lower Hsp27 expression was observed in poorly differentiated cases. Statistical analysis revealed that the Hsp27 expression level in primary
OTSCC is associated with differentiation \((p = 0.0259)\) (Table 3). A marginal association was also observed between Ki67 index and differentiation \((p = 0.0613)\).

Among 80 cases of OTSCC that we examined, follow-up results were available on 42 cases \((52.5\%)\). Median duration of follow-up was 31 months \((range 8–99)\). Among these 42 cases, 12 cases \((28.57\%)\) showed low Hsp27 staining, 18 cases \((42.86\%)\) showed moderate Hsp27 staining, and 12 cases \((28.57\%)\) showed high Hsp27 staining. As illustrated in Figure 2, a striking difference in median survival time was observed between high \((immunohistochemical score of 2 or 3)\) Hsp27 expression group \((over 60 months)\) and low \((immunohistochemical score of 0 or 1)\) Hsp27 expression groups \((less than 30 months)\). Both univariate and multivariate analysis demonstrated the positive effect of high Hsp27 expression for prognosis (Table 4). Based on univariate analysis, the effects of pT and clinical stages on prognosis were also observed.

**Table 2: Correlations among clinical and histopathological features of primary OTSCC**

|         | Age  | Gender | pT stage | pN stage | C stage | Grade | Ki67 | Hsp27 |
|---------|------|--------|----------|----------|---------|-------|------|-------|
| Age     | 0.01 | -0.04  | -0.13    | -0.06    | -0.10   | 0.18  | 0.26 |       |
| Gender  |      | 0.12   | 0.04     | 0.12     | 0.00    | 0.07  | -0.03|       |
| pT stage|      |        |          |          |         |       |      |       |
| pN stage|      |        |          |          |         |       |      |       |
| C stage |      |        |          |          |         |       |      |       |
| Grade   |      |        |          |          |         |       |      |       |
| Ki67    |      |        |          |          |         |       |      |       |
| Hsp27   |      |        |          |          |         |       |      |       |

*Spearman Correlation Coefficients were presented. pT: pathological T-stage; pN: pathological N-stage.

**\(p < 0.05\)

*** \(p < 0.01\)
Discussion and conclusion

Heat shock proteins (HSPs) have been implicated in multiple aspects of tumorigenesis [29]. Hsp27 belongs to a sub-family of small heat shock proteins that are characterized by low molecular masses (12–43 kDa). High levels of Hsp27 expression have been observed in many types of cancers, and tumorigenic potential of Hsp27 expression has been observed in experimental models [30,31]. Its antiapoptotic effect has been well established [32]. The dysregulation of Hsp27 has also been suggested to contribute to invasion and metastasis [33]. More importantly, Hsp27 expression is associated with resistance to cytostatic anticancer drugs (e.g., cisplatin, vincristine and colchicine) and radiation therapy [34-37]. It is striking that Hsp27 is associated with poor prognosis in several tumor types (gastric [12,13], liver [14] and prostate carcinoma [15]), but good prognosis in others (endometrial adenocarcinomas [16,17] and oesophageal cancer [18,19]). These apparent differences in the prognosis of Hsp27 may be partly due to the difference in biological nature of these cancer types, as well as the different treatment options (some of them may be influenced by Hsp27) for these cancers. Collectively, these facts signify the profound roles of Hsp27 in many aspects of tumor progression and response to therapy.

**Table 3: Association of Hsp27 expression and Ki67 index with differentiation**

|           | Hsp27 (IHC) | Ki67 index |
|-----------|-------------|------------|
|           | n | Average | Variance | Average | Variance |
| Well      | 46 | 1.90    | 0.45      | 0.225   | 0.019    |
| Moderately| 20 | 1.74    | 0.47      | 0.302   | 0.025    |
| Poorly    | 14 | 1.34    | 0.39      | 0.316   | 0.040    |

*One-way ANOVA was used to assess the association of Hsp27 and Ki67 with grading.

**Figure 2**

The effects of Hsp27 expression on prognosis. Kaplan-Meier plots of overall survival in patient groups defined by Hsp27 immunohistochemistry (High Hsp27: moderate to high staining, Low Hsp27: no detectable or low staining). The difference in survival rates is statistically significant (p < 0.05).
Currently, the prognostic significance of Hsp27 for OSCC is not clear. While correlation of Hsp27 expression with survival rate was observed in some studies [24,25,28], inverse correlation with survival was implicated in a different study [27], and no prognostic significance was observed by other studies [23,26]. These inconsistencies may in part be due to the heterogeneity in oncogenic pathways. Distinct oncogenic pathways may give rise to a common malignant phenotype (i.e. there may be several different "ways" to get oral cancers). If there are multiple distinct etiologic possibilities (e.g., tobacco smoking, alcohol abuse, HPV infection), and not all are necessary to produce the malignant phenotype, then some of the oncogenic pathways may remain "normal" despite the fact that cancer develops. This may be especially true for OSCC, which arises in various sites (e.g., oral cavity and oropharynx). Tumors from these different sites have distinct clinical presentations and clinical outcomes, and are associated with different risk factors [1] and genetic characteristics [2]. This again complicates the evaluation of prognostic markers because no single etiologic event is consistently present in all cases.

In our present study, by focusing on just one anatomic site (oral tongue), we were able to partially minimize the genetic variation and microenvironment effects among intraoral sites. Our results clearly demonstrated that higher expression level of Hsp27 in primary OTSCC is directly correlated with overall survival rate. Our results also confirmed that the dysregulation of Hsp27 expression is a progressive event that accompanies the OTSCC progression. While the Hsp27 expression is restricted to differentiated suprabasal keratinocytes in normal mucosa, the Hsp27 is expressed in both suprabasal and basal keratinocytes of dysplastic lesions, and then exhibits a diffuse expression pattern in primary OTSCC and metastatic disease. In addition, the reduced Hsp27 expression in primary tumor tissue is associated with poor differentiation. Interestingly, correlation between Hsp27 expression and age was also observed (p < 0.05). A similar observation regarding age and Hsp27 expression in OSCC was also reported in a previous study [24]. Currently, the clinical relevance of this observation is not clear.

It should be noticed that the biological activities of Hsp27 are regulated by phosphorylation of its serines by mitogen-activated protein kinases associated protein kinases (MAPKAPKs) which are themselves activated by phosphorylation by MAP p38 protein kinase [38,39]. In our present study, we do not know the phosphorylation status of the Hsp27. Additional studies may be warranted to further evaluate the prognostic value of Hsp27 which incorporates additional stratification of the phosphorylation status.

In summary, we demonstrated that the dysregulation of Hsp27 expression is a frequent event during the progression of OTSCC. The expression level of Hsp27 is associated with differentiation grade, and reduced expression of Hsp27 is correlated with poor overall survival. Our data suggested that Hsp27 expression may provide prognostic value for patients with OTSCC.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
AW, HY, and XZ conceived the idea for the project and drafted the manuscript. AW, XL, SS, HY and TP performed the laboratory analyses. FS and XZ conducted statistical analyses. AW, XL and DC provided discussions on clinical relevance. AW, XL, DC and XZ drafted the manuscript. All authors read and approved the final manuscript.

Acknowledgements
This work was supported in part by NIH PHS grants CA114688, CA139596, DE014847, DE016569, a grant from Prevent Cancer Foundation (to XZ), and a Science and Technique grant (2004830901002) from Guangdong, China (to AW). XL is supported in part by grants from National Natural Science Foundation (30700952), and Natural Science Foundation of China (30671700). The authors also gratefully recognize the support of the reviewers for their comments and suggestions on the manuscript.

Table 4: The effects of clinical and pathohistological parameters on prognosis*

| Parameter | Univariate Analysis | Multivariate Analysis |
|-----------|---------------------|-----------------------|
|           | HR (95% CI)         | p value               | HR (95% CI)         | p value               |
| Age       | 0.991 (0.958, 1.025) | 0.5941                |                      |                      |
| Gender    | 1.991 (0.849, 4.670) | 0.1135                |                      |                      |
| pT        | 1.622 (1.032, 2.551) | 0.0362                | 2.565 (0.924, 7.121) | 0.0706                |
| pN        | 1.514 (0.893, 2.564) | 0.1233                |                      |                      |
| C Stage   | 1.599 (1.028, 2.485) | 0.0371                | 0.679 (0.179, 2.568) | 0.5680                |
| Grade     | 1.501 (0.889, 2.534) | 0.1291                |                      |                      |
| Ki67      | 0.547 (0.034, 8.761) | 0.6698                |                      |                      |
| Hsp27     | 0.375 (0.190, 0.741) | 0.0048                | 0.234 (0.091, 0.599) | 0.0025                |

* Analysis was done with Cox proportional hazard regression. HR: hazard ratio; 95% CI: 95% confidence interval.
References

1. Dobrossy L: Epidemiology of head and neck cancer: magnitude of the problem. Cancer Metastasis Rev 2005, 24(1):9-17.

2. Timar J, Csakai O, Remenar E, Repassy G, Kasler M: Progression of head and neck squamous cell cancer. Cancer Metastasis Rev 2005, 24(1):107-127.

3. Franceschi D, Gupta R, Spizzo RH, Shah JP: Prognostic value of heat shock proteins or proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci 2006, 31(3):164-172.

4. Franceschi D, Gupta R, Spizzo RH, Shah JP: Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci 2006, 31(3):164-172.

5. Schanz SP, Yu GP: Head and neck cancer incidence trends in young Americans, 1973-1997, with a special analysis for tongue cancer. Arch Otalaryngol Head Neck Surg 2002, 128(3):268-274.

6. Calderwood SK, Khaleque MA, Sawyer DB, Ciocca DR: Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci 2006, 31(3):164-172.

7. Daido T, Ebnerstock P, Preville X, Kotyarov A, Lutsch G, Ducasse T, Carbon MJ, Wierzbicki J, Macfarlane GL: Increasing incidence of oral cancer amongst young persons: what is the aetiology? Oral Oncol 2000, 36(4):387-389.

8. Rogalla T, Ehrnsperger M, Preville X, Kotlyarov A, Lutsch G, Ducasse T, Carbon MJ, Wierzbicki J, Macfarlane GL: Increasing incidence of oral cancer amongst young persons: what is the aetiology? Oral Oncol 2000, 36(4):387-389.

9. Annertz K, Anderson H, Biorklund A, Moller T, Kantola S, Mork J, Olsen JH, Wennberg J: Incidence and survival of squamous cell carcinoma of the tongue in Scandinavia, with special reference to young adults. Int J Cancer 2002, 101(1):95-99.

10. Mehlen P, Kretz-Reny C, Preville X, Arrigo AP: Human hsp27, Drosophila hsp27 and human alphaB-crystallin expression-mediated increase in glutathione is essential for the protective activity of oxidative stress proteins against TNFalpha-induced cell death. Endocr J 1996, 43(1):269-276.

11. Firdaus WJ, Wytenbach A, Diaz-Latou J, Currie RW, Arrigo AP: Analysis of oxidative events induced by expanded polyglutamine huntingtin exon 1 that are differentially restored by expression of heat shock proteins or treatment with an antioxidant. Feds Proc 2006, 273(13):3076-3093.

12. Kapranos N, Konimea A, Konstantinopoulou PA, Savva S, Arterlasis S, Vandroos G, Sotropoulou-Bonikou G, Papavassiliou AG: Expression of the 27-kDa heat shock protein (HSP27) in gastric carcinomas and adjacent normal, metaplastic, and dysplastic gastric mucosa, and its prognostic significance. J Cancer Res Clin Oncol 2002, 128(8):426-432.

13. Takeno S, Noguchi T, Kikuchi R, Sato T, Uchida Y, Yokoyama S: Analysis of the survival period in resectable stage IV gastric cancer. Ann Surg Oncol 2001, 8(3):215-221.

14. King KL, Li AF, Chau GY, Chi CW, Wu CW, Huang CL, Lui WY: Prognostic significance of heat shock protein 27 expression in hepatocellular carcinoma and its relation to histologic grading and survival. Cancer 2000, 88(11):2464-2470.

15. Conford PD, Parsons KE, Desmond AD, Woolfenden A, Fordham M, Neoptolemos JP, Ke Y, Foster CS: Heat shock protein expression independently predicts clinical outcome in prostate cancer. Cancer Res 2000, 60(24):7099-7105.

16. Geisler JP, Geisler HE, Tammela J, Miller GA, Wiemann MC, Zhou Z: A study of heat shock protein expression in human prostate cancer patients. Gynecol Oncol 1999, 72(3):347-350.

17. Piura B, Rabinovich A, Yavelsky V, Wolfson M: [Heat shock proteins and malignancies of the female genital tract]. Harfufud 2002, 14(11):969-972.

18. Kawai K, Shiozaki K, Hoki D, Sakita I, Inoue M, Yano M, Tsujinaka T, Shamma A, Monden M: Prognostic significance of heat shock proteins 27 and 97 in patients with squamous cell carcinoma of the esophagus. Cancer 1999, 85(8):1649-1657.

19. Nakajima M, Kawai H, Miyazaki T, Masuda N, Kato H: Significant correlation between expression of heat shock proteins 27, 70 and lymphocyte infiltration in esophageal squamous cell carcinoma. Cancer Lett 2002, 178(1):99-106.

20. He QY, Chen J, Kuang HF, Yuen AP, Chiu JF: Identification of tumor-associated proteins in oral tongue squamous cell carcinoma by proteomics. Proteomics 2004, 4(1):271-278.

21. Lo MY, Tsai MH, Tsai Y, Hsu CH, Tsai FJ, Huang SY, Tsai CH, Liu CC: Identification of over-expressed proteins in oral squamous cell carcinomas (OSCC) patients by clinical proteomic analysis. Clin Chim Acta 2007, 376(1):101-107.

22. Ye H, Wang A, Lee BS, Yu T, Sheng S, Peng T, Hu S, Crowe DL, Zhou X: Proteomic Based Identification of Manganese Superoxide Dismutase 2 (SOD2) as a Metastasis Marker for Oral Squamous Cell Carcinoma. Cancer Genomics Proteomics 2008, 5(2):85-94.

23. Ito T, Kawabe R, Kurasono Y, Haru M, Kitamura H, Fujita K, Kanisawa M: Expression of heat shock protein 27 in oral squamous cell carcinoma of the tongue: an immunohistochemical study. J Oral Pathol Med 1998, 27(1):18-22.

24. Lo Muzio L, Leonardi R, Mariggiolo MA, Mignogna MD, Rubini C, Vinella A, Panicone G, Giannetti L, Serpico R, Testa NF, et al: HSP27 as possible prognostic marker in patients with oral squamous cell carcinoma. Histol Histopathol 2004, 19(1):119-128.

25. Lo Muzio L, Campisi G, Farina A, Rubini C, Ferrari F, Falaschini S, Leonardi R, Carinci F, Stalbano S, De Rosa G: Prognostic value of HSP27 in head and neck squamous cell carcinoma: a retrospective analysis of 57 tumours. Anticancer Res 2006, 26(2B):1343-1349.

26. Gandour-Edwards R, Trock BJ, Gumerlock P, Donald PJ: Heat shock protein and p53 expression in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 1998, 114(3):610-615.

27. Mese H, Sasaki A, Nakamura S, Ishikawa N, Yoshidome Y, Kishimoto K, Matsumura T: Prognostic significance of heat shock protein 27 (HSP27) in patients with oral squamous cell carcinoma. Oral Oncol Rep 2002, 9(2):341-344.

28. Suzuki H, Sugimura H, Hashimoto K: Overexpression of heat shock protein 27 is associated with good prognosis in the patient with oral squamous cell carcinoma. Br J Oral Maxillofac Surg 2007, 45(2):123-129.

29. Ciocca DR, Calderwood SK: Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 2005, 10(2):86-103.

30. Garrido C, Fromentin A, Bonnotte B, Favre N, Moutet M, Arrigo AP, Mehlen P, Solary E: Heat shock protein 27 enhances the tumorigenicity of immunogenic rat colon carcinoma cell clones. Cancer Res 1998, 58(22):5489-5499.

31. Bruey JM, Paul C, Fromentin A, Hilpert S, Arrigo AP, Solary E, Garrido C: Differential regulation of HSP27 oligomerization in tumor cells grown in vitro and in vivo. Oncogene 2000, 19(42):4853-4863.

32. Garrido C, Brunet M, Didelot C, Zermati Y, Schmitt E, Kroemer G: Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties. Cell Cycle 2006, 5(22):2592-2601.

33. Xu L, Chen S, Bergan RC: MAPKAPK2 and HSP27 are downstream effectors of p38 MAP kinase-mediated matrix metalloproteinase type 2 activation and cell invasion in human prostate cancer. Oncogene 2006, 25(21):2987-2998.

34. Oesterreich S, Weng CN, Qi J, Hilsenbeck SG, Osborne CK, Fuqua SA: The small heat shock protein HSP27 is correlated with growth and drug resistance in human breast cancer cell lines. Cancer Res 1993, 53(19):4443-4448.

35. Rocchi P, So A, Kojima S, Signaevskiy M, Beraldi E, Fazli L, Hurtado-Coll A, Yamakawa K, Gleave M: Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res 2004, 64(18):6595-6602.

36. Aloy MT, Hadchity E, Bionda C, Diaz-Latou J, Claude L, Rousson R, Arrigo AP, Rodriguez-Lafraisse C: Protective role of Hsp27 protein against gamma radiation-induced apoptosis and radiosensitization effects of Hsp27 gene silencing in different human tumor cells. Int J Radiat Oncol Biol Phys 2008, 70(2):543-553.

37. Fortin A, Raybaud-Diogene H, Tetu B, Huot J, Blondeau L, Landry J: Markers of neck failure in oral cavity and oropharyngeal car-
cinomas treated with radiotherapy. Head Neck 2001, 23(2):87-93.

38. Rouse J, Cohen P, Trigon S, Morange M, Alonso-Llamazares A, Zamanillo D, Hunt T, Nebreda AR: A novel kinase cascade triggered by stress and heat shock that stimulates MAPKAP kinase-2 and phosphorylation of the small heat shock proteins. Cell 1994, 78(6):1027-1037.

39. Stokoe D, Engel K, Campbell DG, Cohen P, Gaestel M: Identification of MAPKAP kinase 2 as a major enzyme responsible for the phosphorylation of the small mammalian heat shock proteins. FEBS Lett 1992, 313(3):307-313.

Pre-publication history
The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2407/9/167/prepub